Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEssentra Regulatory News (ESNT)

Share Price Information for Essentra (ESNT)

Share Price is delayed by 15 minutes
Get Live Data
82.60    0.70 (0.85%)
Bid:
82.10
Ask:
82.60
Spread: 0.50 (0.609%)
Market Cap: £234.14m
ESNT Live PriceLast checked at - London Stock Exchange

Intraday Essentra Share Chart

Board Appointment - Chair Designate

23 May 2024 07:00

RNS Number : 5451P
Essentra plc
23 May 2024
 

ESSENTRA PLC

(The "Company" or "Essentra")

 

BOARD APPOINTMENT: CHAIR DESIGNATE

 

Essentra plc, a leading global provider of essential components and solutions, announces the appointment of Steve Good to the Board as independent non-executive chair designate with effect from 1 July 2024.

There will be a four-month induction and handover period during which Paul Lester will remain as chair. After nine years on the Board and in accordance with Provision 19 of the 2018 UK Corporate Governance Code, Paul will stand down as chair and from the Board on 1 November with Steve becoming chair.

Steve has strong and relevant international experience in industrial businesses, manufacturing and B2B markets. He is currently non-executive board chair of Norcros plc and was until 2023 non-executive board chair of Devro plc and Zotefoams plc. He previously served as a non-executive director and remuneration committee chair of Elementis plc and Cape plc and as a non-executive director of Dialight plc.

In his executive career Steve was chief executive of Low & Bonar plc from 2009 to 2014. Prior to joining Low & Bonar, he spent ten years with BTP plc (now part of Clariant) in a variety of leadership positions managing international specialty chemicals businesses.

Steve will serve on the Essentra nomination committee which he will chair when Paul steps down.

Scott Fawcett, Essentra CEO, commented:

"I am very pleased that Steve has joined the Board of Essentra plc. His significant commercial experience gained in both executive and non-executive roles will be invaluable as the Company's independent non-executive chair. I very much look forward to working with him to continue the success of the business.

My Board colleagues and I would like to express our gratitude to Paul Lester for his outstanding leadership and wise counsel over many years. He leaves with our very best wishes."

Steve Good commented:

"It is a great pleasure to join Essentra as it continues to make good progress against its strategic priorities. I look forward to working with the Board as we drive organic and inorganic growth, continue to increase operating efficiencies, margins and returns for stakeholders."

At the date of this announcement, Mr. Good has no interest in the ordinary shares in Essentra plc. 

This announcement is made pursuant to Listing Rule 9.6.11R. There are no other details required to be disclosed under Listing Rule 9.6.13R.

 

 

 

For further information please contact:

Essentra plc

Scott Fawcett, Chief Executive

Emma Reid, Company Secretary

 

Tel: +44 (0)1908 359100

FTI Consulting

Richard Mountain

Ariadna Peretz

FTI_essentra@fticonsulting.com

Tel: +44 (0)20 3727 1340

 

 

 

LEI: 5493007MOZNA03BVNE96

 

 

23 May 2024

 

Notes to Editors

About Essentra plc

Essentra plc is a FTSE 250 company and a leading global provider of essential components and solutions, focusing on the manufacture and distribution of plastic injection moulded, vinyl dip moulded and metal items.

Headquartered in the United Kingdom, Essentra's global network extends to 28 countries worldwide and includes c.3,000 employees, 14 manufacturing facilities, 24 distribution centres and 33 sales & service centres serving c.69,000 customers with a rapid supply of low cost but essential products for a variety of applications in industries such as equipment manufacturing, automotive, fabrication, electronics, medical and renewable energy.

For further information, please visit www.essentraplc.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAZZGZKNZKGDZM
Date   Source Headline
7th Jul 20267:50 amRNSHolding(s) in Company
1st Jul 20263:20 pmRNSTransaction in Own Shares
1st Jul 20263:19 pmRNSTotal Voting Rights
24th Jun 20267:00 amRNSCompletion of the Boteco acquisition
16th Jun 20267:00 amRNSDirectorate change
10th Jun 20269:47 amRNSHolding(s) in Company
1st Jun 20267:00 amRNSTotal Voting Rights
29th May 20262:32 pmRNSTransaction in Own Shares
21st May 202610:55 amRNSResult of AGM
20th May 20267:00 amRNSAcquisition of Boteco Srl
20th May 20267:00 amRNS2026 AGM Trading Update
14th May 20265:15 pmRNSDirector/PDMR Shareholding
12th May 20267:03 amRNSTransaction in Own Shares
1st May 202612:17 pmRNSTotal Voting Rights
29th Apr 20268:12 amRNSTransaction in Own Shares
28th Apr 20263:25 pmRNSDirector/PDMR Shareholding
24th Apr 20263:30 pmRNSDirector/PDMR Shareholding
22nd Apr 20268:15 amRNSTransaction in Own Shares
21st Apr 20264:09 pmRNSDirector/PDMR Shareholding
17th Apr 20267:52 amRNSHolding(s) in Company
15th Apr 202610:06 amRNSDirector/PDMR Shareholding
15th Apr 20268:24 amRNSTransaction in Own Shares
15th Apr 20268:18 amRNSHolding(s) in Company
9th Apr 20268:24 amRNSDirector/PDMR Shareholding
7th Apr 20267:00 amRNSDirector/PDMR Shareholding
7th Apr 20267:00 amRNSHolding(s) in Company
1st Apr 20264:45 pmRNSDirector/PDMR Shareholding
1st Apr 20263:21 pmRNSDirector/PDMR Shareholding
1st Apr 20263:15 pmRNSTransaction in Own Shares
1st Apr 20263:08 pmRNSTotal Voting Rights
30th Mar 20262:00 pmRNSAnnual Financial Report
24th Mar 202610:05 amRNSTransaction in Own Shares
24th Mar 20268:17 amRNSHolding(s) in Company
19th Mar 20268:43 amRNSDirector/PDMR Shareholding
17th Mar 20261:41 pmRNSDirector/PDMR Shareholding
17th Mar 202610:30 amRNSDirectorate change
17th Mar 202610:28 amRNSDirector/PDMR Shareholding
17th Mar 20267:00 amRNSResults for the Full Year Ended 31 December 2025
17th Mar 20267:00 amRNSResults for the Full Year Ended 31 December 2025
16th Mar 20269:40 amRNSTransaction in Own Shares
16th Mar 20269:40 amRNSTransaction in Own Shares
13th Mar 202612:00 pmRNSCompany Secretary Change
9th Mar 20269:00 amRNSNotice of Full Year 2025 Results
9th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTotal Voting Rights
26th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.